Table 2.
Measures taken during the study
| Comorbidity group; n (%) N=482 | Self-assessment group; n (%) N=488 | Adjusted p value | |
|---|---|---|---|
| Cardiovascular diseases | |||
| Blood pressure measurement | 405 (84.0) | 365 (74.8) | 0.006 |
| Purchasing of blood pressure self-measurement devices | 29 (6.0) | 5 (1.0) | 0.006 |
| Diet | 48 (10.0) | 28 (5.7) | 0.04 |
| Smoking cessation | 29 (6.0) | 23 (4.7) | 0.41 |
| Initiation of lipid-lowering therapy | 29 (6.0) | 10 (2.0) | 0.01 |
| Initiation of antiplatelet therapy | 13 (2.7) | 6 (1.2) | 0.30 |
| Serum creatine measurement | 417 (86.5) | 278 (57.0) | 0.006 |
| Nephrology consultation | 9 (1.9) | 13 (2.7) | 0.41 |
| Infection | |||
| Influenza vaccine | 188 (39.0) | 109 (22.3) | 0.005 |
| Pneumococcal vaccine | 54 (11.2) | 28 (5.7) | 0.008 |
| Hepatitis A vaccination | 1 (0.2) | 2 (0.4) | 1.00 |
| Hepatitis B vaccination | 1 (0.2) | 1 (0.2) | 1.00 |
| Meningococcal vaccination | 2 (0.4) | 0 (0) | 0.75 |
| Cancer | |||
| Mammography | 100 (20.7) | 68 (13.9) | 0.02 |
| Smear | 87 (18.0) | 68 (13.9) | 0.32 |
| Blood-in-stool screening | 89 (18.5) | 30 (6.1) | 0.006 |
| Colonoscopy | 26 (5.4) | 20 (4.1) | 0.81 |
| Dermatological consultation | 129 (26.8) | 69 (14.1) | 0.006 |
| Digital rectal examination | 7 (1.5) | 8 (1.6) | 0.81 |
| Urological consultation | 8 (1.7) | 11 (2.3) | 0.81 |
| Osteoporosis | |||
| DEXA scan | 67 (13.9) | 34 (7.0) | 0.006 |
| Initiation of osteoporosis therapy, vitamin D supplementation or calcium supplementation | 169 (35.1) | 72 (14.8) | 0.002 |
| Increased calcium intake | 153 (31.7) | 6 (1.2) | 0.002 |
| Increased physical activity | 126 (26.1) | 39 (8.0) | 0.002 |
| Alcohol discontinuation | 4 (0.8) | 2 (0.4) | 0.40 |
DEXA, Dual Energy-X-Ray Absorptiometry.